Literature DB >> 18706384

Nurses' opinions on appropriate administration of PRN range opioid analgesic orders for acute pain.

Debra B Gordon1, Teresa A Pellino, Gerry Ann Higgins, Chris Pasero, Kathleen Murphy-Ende.   

Abstract

The use of "as needed" or "pro re nata" (PRN) range opioid analgesic orders is a common clinical practice in the management of acute pain, designed to provide flexibility in dosing to meet an individual's unique needs. Range orders enable necessary adjustments in doses based on individual response to treatment. However, PRN range opioid orders have recently come under scrutiny as a source of confusion and as a medication management safety issue. How nurses administer range orders may vary based on their interpretation of the intent of an order, inadequate knowledge of analgesic titration, or exaggerated concerns about opioid safety. The purpose of this study was to investigate nurses' opinions of the appropriate implementation of range orders. Six hundred two nurses from one large academic medical center and one multihospital system completed an online survey using theoretic clinical vignettes to examine their opinions of appropriate analgesic administration practices. The majority of participants chose appropriate responses to the vignettes; however, there was a great deal of variability in responses. Those who had attended pain management courses were more likely to have a higher percentage of appropriate responses than those who had not attended courses. Years in practice and educational level were not significantly related to percentage of appropriate responses; however, there was a trend for nurses with a master's degree to have a higher percentage than nurses with other educational preparation. Consideration of opioid pharmacokinetics can provide logic to develop a new paradigm where range orders are replaced with orders that provide more explicit instructions to titrate an opioid to the most effective dose.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18706384     DOI: 10.1016/j.pmn.2008.03.003

Source DB:  PubMed          Journal:  Pain Manag Nurs        ISSN: 1524-9042            Impact factor:   1.929


  7 in total

1.  Impact of patient-controlled analgesia on pain relief after coronary artery bypass graft surgery: a randomized clinical trial.

Authors:  Sima Lakdizaji; Vahid Zamanzadeh; Mohammad Zia Totonchi; Atoosa Hosseinzadeh
Journal:  J Caring Sci       Date:  2012-11-27

2.  Standardising analgesic administration for nurses: a prospective intervention study.

Authors:  Susanne Schiek; Katharina Moritz; Stefanie J Seichter; Mohamed Ghanem; Georg von Salis-Soglio; Roberto Frontini; Thilo Bertsche
Journal:  Int J Clin Pharm       Date:  2016-09-21

3.  Pro Re Nata Prescription and Perception Difference between Doctors and Nurses.

Authors:  Se Hwa Oh; Ji Eun Woo; Dong Woo Lee; Won Cheol Choi; Jong Lull Yoon; Mee Young Kim
Journal:  Korean J Fam Med       Date:  2014-07-25

4.  Assessment and Management of Postoperative Pain among Nurses at a Resource-Constraint Teaching Hospital in Ghana.

Authors:  Faisal Mahama; Jerry P K Ninnoni
Journal:  Nurs Res Pract       Date:  2019-07-18

Review 5.  Patient Safety and Pro Re Nata Prescription and Administration: A Systematic Review.

Authors:  Mojtaba Vaismoradi; Sara Amaniyan; Sue Jordan
Journal:  Pharmacy (Basel)       Date:  2018-08-29

6.  The Society for Pediatric Anesthesia recommendations for the use of opioids in children during the perioperative period.

Authors:  Joseph P Cravero; Rita Agarwal; Charles Berde; Patrick Birmingham; Charles J Coté; Jeffrey Galinkin; Lisa Isaac; Sabine Kost-Byerly; David Krodel; Lynne Maxwell; Terri Voepel-Lewis; Navil Sethna; Robert Wilder
Journal:  Paediatr Anaesth       Date:  2019-06-11       Impact factor: 2.556

7.  Practical Considerations of PRN Medicines Management: An Integrative Systematic Review.

Authors:  Abbas Mardani; Piret Paal; Christiane Weck; Shazia Jamshed; Mojtaba Vaismoradi
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.